Last reviewed · How we verify

Moderate intensity statin

Yonsei University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Moderate intensity statin is a Small molecule drug developed by Yonsei University. It is currently FDA-approved.

Moderate intensity statins are a type of small molecule medication used to treat conditions such as atherosclerosis, acute coronary syndrome, and dyslipidemias. They are studied in clinical trials for their effectiveness in minimizing stroke risk and improving adherence to medication.

At a glance

Generic nameModerate intensity statin
SponsorYonsei University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moderate intensity statin

What is Moderate intensity statin?

Moderate intensity statin is a Small molecule drug developed by Yonsei University.

Who makes Moderate intensity statin?

Moderate intensity statin is developed and marketed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).

What development phase is Moderate intensity statin in?

Moderate intensity statin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing